13,674 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Pandora Wealth Inc.

Key Points

• Pandora Wealth Inc. acquired 13,674 shares of Pfizer Inc. during the 1st quarter, valued at approximately $346,000, highlighting continued interest from institutional investors.
• Pfizer reported $0.78 earnings per share (EPS) for the recent quarter, exceeding analysts' estimates of $0.58, alongside a 10.3% increase in revenue year-over-year.
• The company declared a quarterly dividend of $0.43, representing a 7.0% yield, with a payout ratio of 91.49%, indicating its commitment to returning value to shareholders.

Pandora Wealth Inc. acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 13,674 shares of the biopharmaceutical company's stock, valued at approximately $346,000.

Other large investors have also bought and sold shares of the company. Clarity Asset Management Inc. purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC raised its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the last quarter. Bayforest Capital Ltd purchased a new position in Pfizer in the 1st quarter worth approximately $28,000. North Capital Inc. purchased a new position in Pfizer in the 1st quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the 4th quarter worth approximately $30,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 1.4%

Shares of PFE stock opened at $24.57 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm has a fifty day moving average price of $24.44 and a 200-day moving average price of $24.50. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.96. The company has a market cap of $139.69 billion, a price-to-earnings ratio of 13.07, a PEG ratio of 0.87 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the business posted $0.60 EPS. Pfizer's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. BMO Capital Markets decreased their price objective on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Jefferies Financial Group boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Leerink Partners decreased their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. Finally, TD Cowen decreased their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.